Insights

LAS VEGAS, June 11, 2026 /PRNewswire/ -- Hyperscale Data, Inc. (NYSE:GPUS), an artificial intelligence ("AI") data center company anchored by Bitcoin ("Hyperscale Data" or the "Company"), announced that it has entered into a Pre-Paid Advance Agreement (the "Agreement") with YA II PN, Ltd., a Cayman Islands exempt limited partnership ("Yorkville"). Pursuant to the Agreement, Yorkville will today make an advance (the "Advance") to the Company in the principal amount of $15,958,000 (the "Principal Face Amount"), subject to a discount of 6% for an actual commitment amount of $15,000,520. The Advance will bear interest at an annual

Omdia has appointed Theresa Lanowitz as Principal Analyst covering vulnerability and risk management within its Cybersecurity go-to-market research practice, bringing decades of experience in software development, industry analysis, and cybersecurity leadership to the role. Lanowitz joins Omdia from LevelBlue, the AT&T cybersecurity spinoff, where she served as Chief Evangelist, leading strategic marketing, communications, public relations, content, and industry outreach. Prior to LevelBlue, she spent seven years at Gartner, leading research on application quality and security, and later founded and led the independent analyst firm Voke for nearly 14 years. At Omdia, Lanowitz will focus

UCITS Funds Provide Climate Focused Core Equities Strategies Northern Trust Asset Management, a leading global investment manager with US$1.4 trillion in assets under management (as of March 31, 2026), today announced the launch of two actively managed UCITS funds, designed to pursue outperformance while efficiently managing climate transition-related risks and opportunities. The NT World Multifactor Focus Select Fund seeks excess returns over a full market cycle, while the NT World Multifactor Select Fund strategy aims to deliver long-term capital growth. Both funds are actively managed using Northern Trust Asset Management's proprietary value, quality, momentum and low volatility sign

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS)) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada. Oculis is a proud sponsor of Clinical Trials at the Summit 2026, which brings together experts from around the world to discuss ongoing clinical trials and the latest data, all with the goal of achieving advances in vitreoretinal care. Details of Oculis' presentation are as follo

CoreWeave, Inc. (Nasdaq: CRWV) ("CoreWeave") announced today that it intends, subject to market and other customary conditions, to offer $3.5 billion (or euro equivalents) in aggregate principal amount of dollar-denominated and euro-denominated senior notes due 2032 (collectively, the "Notes") in a private offering. The Notes will be guaranteed on a senior unsecured basis by certain wholly-owned subsidiaries of CoreWeave. CoreWeave intends to use the proceeds from the offering of the Notes for general corporate purposes, including, without limitation, repayment of outstanding indebtedness, and to pay fees, costs and expenses in connection with the offering of the Notes. The Notes and re

Powered by Infosys Topaz, the collaboration will help unify operations, optimize processes, and enable a future ready healthcare enterpriseBENGALURU, India and KUALA LUMPUR, Malaysia and SINGAPORE, June 11, 2026 /CNW/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE:INFY), a global leader in AI–first business consulting and technology services, today announced a strategic collaboration with IHH Healthcare, one of the world's largest private healthcare providers, to drive a multi–year, enterprise–wide ERP transformation program. This collaboration will enable IHH to standardize and harmonize business processes across all its markets starting with Hong Kong, Malaysia, and Singapore. It will help strea

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress. BALLI-01 clinical trial evaluating la

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c More patients treated with IMAAVY experienced improvement in fatigued and corticosteroid dose reductionse IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function Pivotal results will be presented at EHA 2026 STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistica

- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older - - Data simultaneously published in the New England Journal of Medicine - - Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 year

LONDON, UK / ACCESS Newswire / June 11, 2026 / The Company announces that on 10 June 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.Date of purchase:10 June 2026Aggregate number of ordinary shares purchased:20,000Lowest price paid per share:$ 161.2500Highest price paid per share:$ 164.4500Average price paid per share:$ 163.2003The

LONDON, UK / ACCESS Newswire / June 11, 2026 / Further to its announcement of board changes on 21 May 2026 and the conclusion of necessary due diligence, Guardian Metal Resources plc (NYSE-A:GMTL)(LON:GMET)(OTCQB:GMTLF), a mineral exploration company focused on tungsten within Nevada, USA, announces the formal appointment of Dr Mark Bramley Thorpe to its Board with immediate effect.Mark will be an Independent Non-executive Director of Guardian Metal and will be a member of the Audit Committee. He replaces Mr. Mark Burnett who retired from the Board, as announced previously.Regulatory Disclosures:The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the

EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing Poster presentation at the European Hematology Association (EHA) 2026 Congress, taking place in Stockholm, Sweden COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). Developed with AI-Immunology™, EVX-04 targets multiple non-conv

Kwik Payments utilizes ACI's Payments Orchestration Platform to help merchants reduce checkout friction and drive conversion uplifts of more than 20% ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, today announced that Kwik Payments, a South Africa-based payments service provider (PSP), has successfully gone live on the ACI Payments Orchestration Platform, to power the next phase of digital commerce growth across South Africa and the wider African market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610062114/en/ The partnership represents a pivotal milestone in ACI's expansion across Afr

ORLANDO, June 11, 2026 (GLOBE NEWSWIRE) -- PureCycle Technologies, Inc. ("PureCycle" or "we," "our" or "us") (NASDAQ:PCT) today announced the pricing of its previously announced underwritten public offerings of $250.0 million aggregate principal amount of its 4.75% convertible senior notes due 2032 (the "notes" and such offering, the "Notes Offering"), and, concurrently, 17,661,388 shares of its common stock, par value $0.001 per share (the "common stock"; such offering, the "Common Stock Offering" and, together with the Notes Offering, the "Offerings"), at a public offering price of $8.21 per share, for aggregate gross proceeds of $395.0 million. In addition, PureCycle has granted (i) the

With reference to the press release dated 2 June 2026 by BW LPG Limited ("BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code "BWLP") on key information relating to the cash dividend for Q1 2026, the shares of the Company will be traded ex-dividend on the Oslo Stock Exchange from today and on the New York Stock Exchange from 12 June 2026. The dividend amount is NOK 6.1960 and US$0.67 respectively. About BW LPG BW LPG is the world's leading owner and operator of LPG vessels, with a fleet of about 50 Very Large Gas Carriers (VLGCs), including over 20 vessels powered by LPG dual-fuel propulsion technology. Building on over five decades of LPG shipping experience, the co

4 - MICROVISION, INC. (0000065770) (Issuer)

4 - MICROVISION, INC. (0000065770) (Issuer)

4 - ALTISOURCE PORTFOLIO SOLUTIONS S.A. (0001462418) (Issuer)

144 - IonQ, Inc. (0001824920) (Subject)

144 - IonQ, Inc. (0001824920) (Subject)

144 - IonQ, Inc. (0001824920) (Subject)

144 - IonQ, Inc. (0001824920) (Subject)

4 - Aditxt, Inc. (0001726711) (Issuer)

3/A - Agora, Inc. (0001802883) (Issuer)

SINGAPORE, June 10, 2026 (GLOBE NEWSWIRE) -- Fitness Champs Holdings Limited ("Fitness Champs Holdings", "FCHL" or the "Company") (NASDAQ:FCHL), a distinguished aquatic sports education provider in Singapore, will hold an Extraordinary General Meeting of Shareholders (the "EGM") at 7030 Ang Mo Kio Street, Avenue 5, #04-48, North Star@AMK, Singapore at 10 a.m. Singapore Time on June 29, 2026 (10 p.m. Eastern Standard Time on June 28, 2026). Holders of the Company's class A ordinary shares (the "Class A Ordinary Shares") and class B ordinary shares (the "Class B Ordinary Shares" and, together with the Class A Ordinary Shares, the "Ordinary Shares") listed in the register of members of the C